The biotech pharmaceutical sector fights against COVID-19 (STAB, PFE, MRNA, BNTX, LLY and NVAX)

Biotech pharmaceutical stocks are generating profits in 2022 while developing more effective COVID-19 vaccines and treatments for variants. Investors can buy these stocks now that new drugs are hitting the market.

Biotech Pharmaceutical analysts see the pandemic evolving into an endemic. Profits are ahead as countries around the world seek vaccines against COVID-19. Biotech R&D for specialty COVID-19 vaccines offers investors profits as anti-COVID-19 drug candidates undergo clinical studies before final FDA approval.

COVID-19 vaccines are a key opportunity for investors in biotech pharmaceuticals. We are now two years since the start of the pandemic. Biotech Pharmaceuticals created the vaccines to treat COVID-19 and its subsequent variants. Today, leading biotechnology companies are launching clinical studies designed to treat largely non-hospitalized but acute patients around the world.

The catalyst for this sector for investors is profit and dividends. Statera Biopharma, Inc. STAB is a clinical-stage biopharmaceutical company investigating the treatment of patients with acute COVID-19 infection over the long term. Put STAB stocks on your watch list as this compelling biotech research continues and profits are to come.

Biotech Pharmaceutical Sector Soars as COVID-19 Fighter

— The best known is Pfizer DFP which this week launched a study of Paxlovid, its new oral antiviral pill for the treatment of COVID-19. The Phase II/III pediatric study of the pill is intended for non-hospitalized, mediatric and symptomatic patients.

In December 2021, the FDA cleared the pill for emergency use in high-risk adults and children at least 12 years of age and older. Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.

STAB studies treatment of patients infected with acute COVID-19

— Statera Biopharma, Inc. STAB is a clinical-stage biopharmaceutical company investigating the treatment of patients with acute COVID-19 infection. Investor timing is critical. The STAB has filed with the FDA its Phase 1 clinical trial protocol for the investigational long-distance treatment of COVID-19.

This is a pilot study of long-distance COVID-19 STAB drug treatment STAT-205. Michael K. Handley, CEO, says the company has a vibrant “clinical stage pipeline” and recently submitted a Phase 3 clinical trial protocol to the FDA for its candidate STAT-201 for the treatment pediatric Crohn’s disease.

In its STAT-205 study, STAB is investigating acute COVID-19 infection. The STAB hopes to develop preliminary data from this study this year.

In the revised preliminary financial statements for the year ended 31 December 2021, STAB now indicates that it has reached positive equity at the end of the financial year.

mRNA studies for Omicron-specific booster drug candidate

— Moderna, Inc. mRNA, having developed a COVID-19 vaccine now named Spikevax is now in a mid-stage study of its Omicron-specific booster candidate. The company already has a phase three study planned in the UK

MRNA has entered into advance purchase agreements worth $19 billion for its COVID-19 vaccine with several countries for 2022. The company believes COVID-19 will become endemic in 2022 and says it will generate more than sales in the second half of 2022 than in the first half. BioNTech tests its fourth vaccine against COVID-19

—BioNTech BNTX is testing a fourth-generation COVID-19 vaccine. The biotech pharmaceutical industry expects the pandemic to become rampant this year. Performance may therefore be lower than expected in the short term.

BNTX reached $19 billion in volume in 2021. It will report its fourth quarter results later this month. Analysts don’t expect the company to match 2021 sales, but predict a growth spurt by 2026. BNTX and Regeneron Pharmaceuticals REGN have together generated billions of dollars in sales of COVID-19 vaccines.

LLY COVID-19 drug reduces risk in hospitalized patients

— Eli Lilly and company THERE IS has preliminary research from the UK that shows its drug Baricitinib successfully reduces the risk of death in hospitalized COVID-19 patients. The drug was originally developed as a treatment for rheumatoid arthritis by Eli Lilly in conjunction with Incyte Corp.

NVAX seeks COVID-19 drug candidate

—Novavax NVAX is seeking a COVID-19 drug candidate, NVX:CoV2373. It has already obtained approvals from several countries as well as a WHO emergency use list.

Biotech stocks can pay off big

Biotech stocks offer investors drug candidates and innovative research that pay off big if commercially successful.

Keep STAB stocks on your watchlist as biopharmaceutical companies rise in value as clinical research studies succeed. Link to more news at

Disclaimer: Capital Gains Report ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed dealer, dealer or registered investment adviser. It should be expressly understood that in no way does the information published here represent a recommendation to buy or sell a security. Our reports/press releases are commercial advertising and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in stocks featured on our site or in emails unless you can afford to lose your entire investment. The information made available by CGR is not intended to be, nor does it constitute, investment advice or recommendations. Contributors can buy and sell titles before and after any particular article, report, and publication. Under no circumstances CGR. be liable to any member, guest or third party for any damages of any kind arising from the use of any content or other material published or made available by CGR., including, without limitation, any loss of investment, loss of profit, loss of opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. CGR. strongly urges you to conduct a full and independent investigation of the respective companies and consider all relevant risks. Readers are encouraged to consult the periodic reports of the SEC: Forms 10-Q, 10K, Form 8-K, Insider Reports, Forms 3, 4, 5, Schedule 13D. For certain content, CGR., its authors, contributors or agents, may be compensated for the preparation of research, video graphics and editorial content. CGR was compensated one thousand five hundred dollars by wire transfer per release by Crossroads to produce and syndicate content for STAB. In connection with this content, readers, subscribers and website visitors should read the full disclaimers and financial statement found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor regarding forward-looking statements. Any statements that express or imply discussions regarding predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made, which involve a number of risks and uncertainties that could cause actual results or events to differ materially from those currently anticipated. . Forward-looking statements in this action can be identified by the use of words such as plans, foresee, expect, anticipate, estimate, believe, understand, or by statements indicating certain actions and quote; can, could or could happen. Understand that there is no guarantee that past performance will be indicative of future results. Investing in microcap and growth stocks is highly speculative and involves an extremely high degree of risk. It is possible that an investor’s investment may be lost or depreciated due to the speculative nature of the companies featured.

Media Contact
Company Name: Capital Gains Report
Contact: Marc McKelvie
E-mail: Send an email
The country: United States

Press release distributed by

To see the original version on ABNewswire, visit: Biotech Pharmaceutical Sector Fights COVID-19 (STAB, PFE, MRNA, BNTX, LLY and NVAX)

Comments are closed.